Product Description
It is a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI) in extended release tablet form.
Mechanisms of Action: NRI Inhibitor, SRI Inhibitor, DRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Shandong Pharmaceutical
Company Location: Asia Pacific
Company Founding Year: 1993
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Depressive Disorder, Major
Phase 1: Depressive Disorder, Major|Depressive Disorder|Neuralgia|Chronic Pain|Osteoarthritis|Fibromyalgia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20210346 |
CTR20210346 | P1 |
Completed |
Depressive Disorder|Osteoarthritis|Fibromyalgia|Chronic Pain|Neuralgia |
2021-04-06 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT03822065 |
LY03005/CT-USA-105 | P1 |
Completed |
Depressive Disorder, Major |
2019-02-16 |
50% |
2019-08-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03733574 |
LY03005/CT-USA-106 | P1 |
Completed |
Depressive Disorder, Major |
2018-07-17 |
2019-03-22 |
Treatments |
|
NCT03357796 |
LY03005/CT-USA-104 | P1 |
Completed |
Depressive Disorder, Major |
2017-12-22 |
20% |
2019-03-21 |
Treatments |
NCT02988024 |
LY03005/CT-USA-103 | P1 |
Completed |
Depressive Disorder, Major |
2016-12-28 |
2019-03-21 |
||
NCT03785652 |
LY03005-CHN-204 | P1 |
Completed |
Depressive Disorder, Major |
2015-10-31 |
2019-03-22 |
Treatments |
|
NCT02271412 |
LY03005 MAD | P1 |
Completed |
Depressive Disorder, Major |
2015-03-01 |
2019-03-20 |
Treatments |
|
NCT02055300 |
LY03005SAD | P1 |
Completed |
Depressive Disorder, Major |
2014-08-01 |
2019-03-20 |
||
NCT04853407 |
LY03005/CT-CHN-305 | P3 |
Completed |
Depressive Disorder, Major |
2020-12-24 |
2021-11-16 |
Patient Enrollment|Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/23/2021 |
News Article |
Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets |
|
08/24/2021 |
News Article |
Major Depressive Disorder- Market Insight, Epidemiology and Market Forecast -2030 |
|
03/20/2020 |
News Article |
Major Depressive Disorder (MDD) Market Insights, Epidemiology and Forecast to 2028 - ResearchAndMarkets.com |
|
03/13/2020 |
News Article |
Global Major Depressive Disorder (MDD) Market Insights, 2017-2028 |